Integrating Contextual MiRNA and Protein Signatures for Diagnostic and Treatment Decisions in Cancer

Overview

Journal Expert Rev Mol Diagn

Specialty Molecular Biology

Date 2011 Oct 26

PMID 22022944

Citations 20

Authors

Lorenzo F Sempere

Affiliations

Soon will be listed here.

Abstract

The promise of personalized medicine is highly dependent on the identification of biomarkers that inform diagnostic decisions and treatment options, as well as on the accurate, rapid and cost-effective detection and interpretation of these biomarkers. miRNAs, which are short noncoding regulatory RNAs, are rapidly emerging as a novel class of biomarkers with a unique set of biological and chemical properties that makes them very appealing candidates for theranostic applications in cancer. Since the utility of some protein-encoding gene biomarkers is already exploited in routine clinical practice, it will be important to identify areas in which miRNAs provide complementary or superior information to these existing (and other translational) biomarkers to enhance the diagnostic, prognostic and predictive power of molecular characterization of tumors. In this article, the challenges and opportunities for integration of miRNA-based assays in the clinical toolkit to improve care and management of patients afflicted with solid tumors will be discussed.

Citing Articles

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients.

Sanchez-Cabrero D, Garcia-Guede A, Burdiel M, Pernia O, Colmenarejo-Fernandez J, Gutierrez L Int J Mol Sci. 2023; 24(14).

PMID: 37511221 PMC: 10380700. DOI: 10.3390/ijms241411464.

Identification of key differentially expressed mRNAs and microRNAs in non-small cell lung cancer using bioinformatics analysis.

Wang W, Wang S, Pan L Exp Ther Med. 2020; 20(4):3720-3732.

PMID: 32855723 PMC: 7444408. DOI: 10.3892/etm.2020.9105.

Differentially expressed circulating miRNAs in postmenopausal osteoporosis: a meta-analysis.

Pala E, Denkceken T Biosci Rep. 2019; 39(5).

PMID: 31023966 PMC: 6522747. DOI: 10.1042/BSR20190667.

Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies.

Hoey C, Liu S Res Rep Urol. 2019; 11:29-42.

PMID: 30881943 PMC: 6398395. DOI: 10.2147/RRU.S165625.

Development of novel predictive miRNA/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach.

Makondi P, Wei P, Huang C, Chang Y PLoS One. 2019; 14(2):e0211968.

PMID: 30807603 PMC: 6391078. DOI: 10.1371/journal.pone.0211968.

References

Hanson J, Tangrea M, Kim S, Armani M, Pohida T, Bonner R . Expression microdissection adapted to commercial laser dissection instruments. Nat Protoc. 2011; 6(4):457-67. PMC: 4795005. DOI: 10.1038/nprot.2010.202. View

Ketting R . microRNA Biogenesis and Function : An overview. Adv Exp Med Biol. 2011; 700:1-14. DOI: 10.1007/978-1-4419-7823-3_1. View

Hipp J, Cheng J, Hanson J, Yan W, Taylor P, Hu N . SIVQ-aided laser capture microdissection: A tool for high-throughput expression profiling. J Pathol Inform. 2011; 2:19. PMC: 3073068. DOI: 10.4103/2153-3539.78500. View

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Saba R, Schratt G . MicroRNAs in neuronal development, function and dysfunction. Brain Res. 2010; 1338:3-13. DOI: 10.1016/j.brainres.2010.03.107. View

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

Camps C, Buffa F, Colella S, Moore J, Sotiriou C, Sheldon H . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5):1340-8. DOI: 10.1158/1078-0432.CCR-07-1755. View

Yu S, Chen H, Chang G, Chen C, Chen H, Singh S . MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13(1):48-57. DOI: 10.1016/j.ccr.2007.12.008. View

10.

Kim M, Kim T, Kong S, Kwon S, Bae C, Choi J . Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS One. 2010; 5(5):e10441. PMC: 2862720. DOI: 10.1371/journal.pone.0010441. View

11.

Brennan D, OConnor D, Rexhepaj E, Ponten F, Gallagher W . Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer. 2010; 10(9):605-17. DOI: 10.1038/nrc2902. View

12.

Weigelt B, Hu Z, He X, Livasy C, Carey L, Ewend M . Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005; 65(20):9155-8. DOI: 10.1158/0008-5472.CAN-05-2553. View

13.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

14.

Bhattacharjee A, Richards W, Staunton J, Li C, Monti S, Vasa P . Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98(24):13790-5. PMC: 61120. DOI: 10.1073/pnas.191502998. View

15.

Marchini C, Montani M, Konstantinidou G, Orru R, Mannucci S, Ramadori G . Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One. 2010; 5(11):e14131. PMC: 2994727. DOI: 10.1371/journal.pone.0014131. View

16.

Bartel D, Chen C . Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004; 5(5):396-400. DOI: 10.1038/nrg1328. View

17.

Nelson P, Baldwin D, Kloosterman W, Kauppinen S, Plasterk R, Mourelatos Z . RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2005; 12(2):187-91. PMC: 1370897. DOI: 10.1261/rna.2258506. View

18.

Haber D, Gray N, Baselga J . The evolving war on cancer. Cell. 2011; 145(1):19-24. DOI: 10.1016/j.cell.2011.03.026. View

19.

Gallardo E, Navarro A, Vinolas N, Marrades R, Diaz T, Gel B . miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30(11):1903-9. DOI: 10.1093/carcin/bgp219. View

20.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K . Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009; 27(12):2030-7. DOI: 10.1200/JCO.2008.19.4134. View